|
A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). |
|
Ecaterina Elena Ileana Dumbrava |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie/Genentech; Agile Therapeutics; AMAG Pharmaceuticals; Endo Pharmaceuticals; Lilly; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - Neoleukin Therapeutics |
Stock and Other Ownership Interests - Johnson & Johnson; Pfizer |
Consulting or Advisory Role - Genentech/Roche; Partners Therapeutics; Tillotts Pharma |
Research Funding - Novartis |
|
|
Consulting or Advisory Role - Regeneron |
Research Funding - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Tillotts Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting |
Consulting or Advisory Role - Alcimed; Bayer; Celgene; Defined Health; Five Prime Therapeutics; Genentech; Gfk; GlaxoSmithKline; Imvax; Leerink; Leerink; Maverick Therapeutics; Merck; PureTech; Putnam Associates; Sobi |
Research Funding - Amgen (Inst); Merck |
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst) |
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech |
|
|
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb |
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Merck; Novartis; Pfizer |
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Pfizer (Inst) |
Expert Testimony - Boehringer Ingelheim |
|
|
Consulting or Advisory Role - Sanofi |
Research Funding - Bristol-Myers Squibb; Genentech; Sanofi |
|
|
Consulting or Advisory Role - Array BioPharma; Biodesix; Celldex; Corvus Pharmaceuticals; Genentech/Roche; Immunocore; Iovance Biotherapeutics; Merck; Nektar; Pfizer |
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Apexigen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech/Roche |
Research Funding - Bristol-Myers Squibb |
|
|
Stock and Other Ownership Interests - Drishti |
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Corvus Pharmaceuticals; Genentech; Harbour BioMed; MedTree (I); Mundipharma; Nodus Therapeutics; Seagen; ShangPharma Innovation |
Research Funding - ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Pfizer (Inst); Plexxikon (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
Hussein Abdul-Hassan Tawbi |
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst) |